IKT · CIK 1750149
What Inhibikase Therapeutics, Inc. told the SEC could break it.
Inhibikase's disclosures center on its dependence on China-based manufacturing and the trade policy bearing on it. Its current and future drug candidates are expected to be made in whole or in part by companies in China, a reliance it expects to continue, which puts it directly in the path of a September 2025 U.S. policy imposing a 100% tariff on brand-name or patented drugs absent U.S. manufacturing, plus possible tariffs on imported APIs that would raise the cost of its clinical-trial materials. That supply chain is also narrow on inputs — a disruption in limited or sole-source raw materials could halt manufacturing until a new source is qualified. Separately, because all of its novel compounds were funded in part by the U.S. government, they are subject to federal march-in rights that could let the government license the IP to others.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- 100% tariff on brand/patented drugs; China API tariffshigh
A September 2025 U.S. policy of a 100% tariff on brand-name/patented drugs (absent U.S. manufacturing) and possible tariffs on imported APIs could raise the cost of Inhibikase's clinical-trial materials sourced from China.
“In addition, on September 25, 2025, the current U.S. administration announced a 100% tariff on brand-name or patented drugs unless pharmaceutical companies expand their manufacturing operations in the U.S.”
SEC filing →As of 2026 - federal march-in rights on government-funded compoundsmedium
All of Inhibikase's novel compounds were funded in whole or in part by the U.S. government and are subject to federal march-in rights, which could let the government license the IP to others.
“All of our novel compounds were funded in whole or in part by the U.S. government and are therefore subject to federal march-in rights.”
SEC filing →As of 2026
Geographic concentration
- drug-candidate manufacturing dependent on Chinamedium
Inhibikase's current and future product candidates are expected to be manufactured in whole or in part by companies in China, and it expects to remain partially dependent on Chinese manufacturers for the foreseeable future.
“Our current and future product candidates are expected to be manufactured in whole or in part by companies that are located in China.”
Sole-source dependency
- limited / sole-source raw materials for product candidatesmedium
Inhibikase relies on suppliers for raw materials and a supply interruption in limited or sole-source materials could halt manufacture of its product candidates until a new source is qualified.
“Any supply interruption in limited or sole source draw materials could materially harm the ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch